<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368025">
  <stage>Registered</stage>
  <submitdate>5/03/2015</submitdate>
  <approvaldate>13/05/2015</approvaldate>
  <actrnumber>ACTRN12615000466549</actrnumber>
  <trial_identification>
    <studytitle>Comparative effect of resuscitation with hypertonic saline versus normal saline after extracorporeal circulation during cardiovascular surgery in the Intensive Care Unit (ICU)</studytitle>
    <scientifictitle>Comparative effect of resuscitation with hypertonic saline versus normal saline on lactate clearance in patients hospitalized in ICU that underwent extracorporeal circulation during valve replacement or coronary artery bypass grafting
</scientifictitle>
    <utrn>U1111-1167-4074</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crystalloid resuscitation after valve replacement surgery and coronary artery bypass surgery that underwent extracorporeal circulation</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>We administer  intravenously infused over 30 minutes Hypertonic Saline with a concentration of 7.5% in a dose of 4 cc x kg of predicted body weight when the patients arrive to the ICU after a replacement valve surgery or a coronary artery bypass graft surgery that underwent extracorporeal circulation.</interventions>
    <comparator>We administer  intravenously infused over 30 minutes Normal Saline with a concentration of 0.9% in a dose of 4 cc x kg of predicted body weight when the patients arrive to the ICU after a replacement valve surgery or a coronary artery bypass graft surgery that underwent extracorporeal circulation.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The blood lactate sample was obtained from central venous catheter immediately after the admission of the patient in the ICU and then again after 6 hours, 12 hours and 24 hours.

Lactate is measured in the laboratory by chemical oxidation method.
</outcome>
      <timepoint>Assessed on admission of the patient in the ICU and then again after 6 hours, 12 hours and 24 hours.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The cardiac index was measured by the thermodilution principle with a pulmonary artery catheter after the admission of the patient in the ICU and then again at 30 minutes, 4 hours, 6 hours, 12 hours and 24 hours.</outcome>
      <timepoint>Assessed on admission of the patient in the ICU and then again at 30 minutes, 4 hours, 6 hours, 12 hours and 24 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The sample of mixed venous oxygen saturation  was obtained with a pulmonary artery catheter after the admission of the patient in the ICU and then again at 30 minutes, 4 hours, 6 hours, 12 hours and 24 hours.

I - Stat system was used for measuring the mixed venous oxygen saturation.</outcome>
      <timepoint>Assessed on admission of the patient in the ICU and then again at 30 minutes, 4 hours, 6 hours, 12 hours and 24 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ICU hospitalization length</outcome>
      <timepoint>time of ICU hospitalisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>mortality</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with signed informed consent older than 18 years old
Patients admitted in the ICU after valve replacement surgery or coronary artery bypass surgery that underwent extracorporeal circulation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients that withdraw the informed consent by himself or by their family at any time during the intervention
Heart transplant surgery
Patients that do not fulfill the study protocol
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>We used numbered containers without label of crystalloid solution to be used in both groups of the trial, since the 7.5% hypertonic saline solution and the normal saline solution are alike, neither the patient, medical staff or the investigators were aware of what was the solution used during the trial. </concealment>
    <sequence>Permuted block  randomization using a random number generator (Ralloc Stata Co. 8,2)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>5/04/2013</anticipatedstartdate>
    <actualstartdate>18/04/2013</actualstartdate>
    <anticipatedenddate>1/05/2014</anticipatedenddate>
    <actualenddate>20/01/2015</actualenddate>
    <samplesize>102</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Antioquia/Medellin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Ray Mendoza Franco</primarysponsorname>
    <primarysponsoraddress>Hospital San Vicente Fundacion
Calle 64 # 51 D - 154 
Medellin/Colombia</primarysponsoraddress>
    <primarysponsorcountry>Colombia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Luis Horacio Atehortua Lopez</sponsorname>
      <sponsoraddress>Hospital San Vicente Fundacion
Calle 64 # 51 D - 154 
Medellin/Colombia</sponsoraddress>
      <sponsorcountry>Colombia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized double blind controlled trial that compares 7.5% hypertonic saline solution versus normal saline solution, in the resuscitation of the patients that underwent extracorporeal circulation surgery once they arrive in the ICU. The primary endpoint was to assess the lactate clearance within each arm of the study.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica Medica del Hospital San Vicente Fundacion</ethicname>
      <ethicaddress>Antioquia/Medellin
Street 64 # 51D - 38</ethicaddress>
      <ethicapprovaldate>26/02/2013</ethicapprovaldate>
      <hrec>2013030305</hrec>
      <ethicsubmitdate>21/12/2012</ethicsubmitdate>
      <ethiccountry>Colombia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368025-2013feb26 solicitud de diligenciamiento de acta de compromiso.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368025-consentimiento SSH.docx</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/368025-FORMULARIO SSH VS SH.doc</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Luis Horacio Atehortua Lopez </name>
      <address>Hospital San Vicente Fundacion
Antioquia/Medellin Street 64 Number 51 D - 154. 
</address>
      <phone>+573177891868</phone>
      <fax />
      <email>lhatehortua@gmail.com</email>
      <country>Colombia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Ray Mendoza Franco</name>
      <address>Centros Especializados San Vicente Fundacion
Rionegro/Antioquia/ Colombia
Vereda La Convencion, Via Aeropuerto Llanogrande Km 2.3. </address>
      <phone>+573006548025</phone>
      <fax />
      <email>ray.mendoza@rocketmail.com</email>
      <country>Colombia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Ray Mendoza Franco</name>
      <address>Centros Especializados San Vicente Fundacion
Rionegro/Antioquia/ Colombia
Vereda La Convencion, Via Aeropuerto Llanogrande Km 2.3. </address>
      <phone>+573006548025</phone>
      <fax />
      <email>ray.mendoza@rocketmail.com</email>
      <country>Colombia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Ray Mendoza Franco</name>
      <address>Antioquia/Medellin street 42 - 63A #198 </address>
      <phone>+573006548025</phone>
      <fax />
      <email>ray.mendoza@rocketmail.com</email>
      <country>Colombia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>